Lunai Bioworks Inc (LNAI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.16-30.20%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LNAI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.
Stated in a supplied disclosure. Management reported: “The Board took this action because of the staff determination and the Company’s financial condition, and concluded that the cost of continued listing and SEC reporting is not justified.” “The Company intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about November 2, 2026, and expects the delisting to become effective on or about November 12, 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The Reverse Stock Split is intended primarily to increase the market price per share of the Company’s Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), w…
Stated in 1 of 1 supplied quarters. Management reported: “The Reverse Stock Split is intended primarily to increase the market price per share of the Company’s Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Capital Market.”
“The Reverse Stock Split is intended primarily to increase the market price per share of the Company’s Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), w…”
Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform.
Stated in 1 of 1 supplied quarters. Management reported: “Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform.” “The Company is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.”
“Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform.”
Develop precision therapeutics for central nervous system diseases using clinical data, machine learning, and in vivo validation.
Initiate and vigorously pursue legal action against parties engaged in naked short selling to protect shareholder value.
Over the trailing year it converted 0.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
39 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.